Literature DB >> 29874983

Plasma cholesterol and lipoprotein levels in relation to tumor aggressiveness and survival in HCC patients.

Brian I Carr1, Gianluigi Giannelli2, Vito Guerra2, Edoardo G Giannini3, Fabio Farinati4, Gian Ludovico Rapaccini5, Maria Di Marco6, Marco Zoli7, Eugenio Caturelli8, Alberto Masotto9, Roberto Virdone10, Rodolfo Sacco11, Franco Trevisani12.   

Abstract

BACKGROUND AND AIMS:: Hepatocellular carcinoma is associated with several chronic liver diseases, especially chronic hepatitis B virus, hepatitis C virus, and alcoholism. It is increasingly appreciated that obesity/metabolic syndrome is also associated with chronic liver disease and subsequent hepatocellular carcinoma.
METHODS: : We retrospectively investigated the serum lipid profiles in a large hepatocellular carcinoma cohort, associated predominantly with the hepatitis B virus, hepatitis C virus, alcohol or nonalcoholic steatohepatitis. The cohort was examined both as a whole, as well as stratified by etiology.
RESULTS: : We found significant associations between parameters of hepatocellular carcinoma biology such as maximum tumor diameter, portal vein thrombosis, tumor multifocality or alpha-fetoprotein levels and individual lipid components, including total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides and body mass index. In a final multiple linear regression model considering all lipid variables together, only high-density lipoprotein cholesterol was significantly associated with the tumor Tumor Aggressiveness Index. High-density lipoprotein cholesterol was found to have a statistically higher hazard ratio for death than low high-density lipoprotein cholesterol levels (Cox). On examination by etiological group, alpha-fetoprotein levels were significantly higher in patients with hepatitis C virus compared to those with alcohol or nonalcoholic steatohepatitis, but maximum tumor diameter, tumor multifocality and portal vein thrombosis were similar across etiological groups. Nonalcoholic steatohepatitis patients had significantly less cirrhosis than other groups and hepatitis B virus patients had significantly higher cholesterol and low-density lipoprotein cholesterol levels than hepatitis C virus patients.
CONCLUSIONS: : This is the first report, to our knowledge, of a relationship between serum lipid parameters and indices of hepatocellular carcinoma growth, invasion and aggressiveness, as well as with survival.

Entities:  

Keywords:  Hepatocellular carcinoma; aggressiveness; lipids; survival

Mesh:

Substances:

Year:  2018        PMID: 29874983     DOI: 10.1177/1724600818776838

Source DB:  PubMed          Journal:  Int J Biol Markers        ISSN: 0393-6155            Impact factor:   2.659


  12 in total

1.  Acoustically Driven Microbubbles Enable Targeted Delivery of microRNA-Loaded Nanoparticles to Spontaneous Hepatocellular Neoplasia in Canines.

Authors:  Sukumar Uday Kumar; Arsenii V Telichko; Huaijun Wang; Dongwoon Hyun; Eric G Johnson; Michael S Kent; Robert B Rebhun; Jeremy J Dahl; William T N Culp; Ramasamy Paulmurugan
Journal:  Adv Ther (Weinh)       Date:  2020-11-12

2.  Plasma lipids, tumor parameters and survival in HCC patients with HBV and HCV.

Authors:  H Akkiz; B I Carr; V Guerra; R Donghia; K Yalçın; U Karaoğullarından; E Altıntaş; A Özakyol; H Şimşek; H Y Balaban; A Balkan; A Uyanıkoğlu; N Ekin; A Delik
Journal:  J Transl Sci       Date:  2020-09-16

3.  Novel Timosaponin AIII-Based Multifunctional Liposomal Delivery System for Synergistic Therapy Against Hepatocellular Carcinoma Cancer.

Authors:  Lijuan Zhang; Shengan Zhang; Min Jiang; Lu Lu; Yue Ding; Ninghui Ma; Yuan Zhao; Sihan Xuchen; Nailian Zhang
Journal:  Int J Nanomedicine       Date:  2021-08-16

4.  Serum levels of inflammatory markers CRP, ESR and albumin in relation to survival for patients with hepatocellular carcinoma.

Authors:  Hikmet Akkiz; Brian I Carr; Harika G Bag; Ümit Karaoğullarından; Kendal Yalçın; Nazim Ekin; Ayşegül Özakyol; Engin Altıntaş; Hatice Y Balaban; Halis Şimşek; Ahmet Uyanıkoğlu; Ayhan Balkan; Sedef Kuran; Oğuz Üsküdar; Yakup Ülger; Burak Güney; Anil Delik
Journal:  Int J Clin Pract       Date:  2020-12-12       Impact factor: 2.503

5.  STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway.

Authors:  Laura Conde de la Rosa; Carmen Garcia-Ruiz; Carmen Vallejo; Anna Baulies; Susana Nuñez; Maria J Monte; Jose J G Marin; Lucia Baila-Rueda; Ana Cenarro; Fernando Civeira; Josep Fuster; Juan C Garcia-Valdecasas; Joana Ferrer; Michael Karin; Vicent Ribas; Jose C Fernandez-Checa
Journal:  J Hepatol       Date:  2021-01-27       Impact factor: 30.083

6.  Emodin Sensitizes Hepatocellular Carcinoma Cells to the Anti-Cancer Effect of Sorafenib through Suppression of Cholesterol Metabolism.

Authors:  Young-Seon Kim; Yoon-Mi Lee; Taek-In Oh; Dong Hoon Shin; Geon-Hee Kim; Sang-Yeon Kan; Hyeji Kang; Ji Hyung Kim; Byeong Mo Kim; Woo Jong Yim; Ji-Hong Lim
Journal:  Int J Mol Sci       Date:  2018-10-12       Impact factor: 5.923

Review 7.  Lipoprotein Drug Delivery Vehicles for Cancer: Rationale and Reason.

Authors:  Jaideep Chaudhary; Joseph Bower; Ian R Corbin
Journal:  Int J Mol Sci       Date:  2019-12-15       Impact factor: 5.923

8.  Association of Obesity With Survival Outcomes in Patients With Cancer: A Systematic Review and Meta-analysis.

Authors:  Fausto Petrelli; Alessio Cortellini; Alice Indini; Gianluca Tomasello; Michele Ghidini; Olga Nigro; Massimiliano Salati; Lorenzo Dottorini; Alessandro Iaculli; Antonio Varricchio; Valentina Rampulla; Sandro Barni; Mary Cabiddu; Antonio Bossi; Antonio Ghidini; Alberto Zaniboni
Journal:  JAMA Netw Open       Date:  2021-03-01

9.  Impacts of the SOAT1 genetic variants and protein expression on HBV-related hepatocellular carcinoma.

Authors:  Yulong Chen; Xunjun Yang; Yao Chen; Guorong Chen; Cheryl A Winkler; Ping An; Jianxin Lyu
Journal:  BMC Cancer       Date:  2021-05-26       Impact factor: 4.430

Review 10.  From Liver Fat to Cancer: Perils of the Western Diet.

Authors:  Ju Youn Kim; Feng He; Michael Karin
Journal:  Cancers (Basel)       Date:  2021-03-04       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.